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Abstract
Background
Patient empowerment is a key factor in improving health outcomes.
Objective
To evaluate the psychometric properties of the Spanish version of the questionnaire on
Patient Empowerment in Long-Term Conditions (PELC) that evaluates the degree of
empowerment of patients with chronic diseases.
Methods
Three measurements were made (at baseline, 2 weeks and 12 weeks) of quality of life
(QoL), self-care, self-efficacy and empowerment. Reliability was evaluated as internal con-
sistency for the entire sample. Test-retest reproducibility was evaluated for patients who
were stable from baseline to week 2 (n = 70). Validity was analysed (n = 124) as baseline
correlations with QoL, self-care, self-efficacy, clinical data and psychosocial variables. Sen-
sitivity to change was analysed in terms of effect size for patients who had improved
between baseline and week 12 (n = 48).
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The study was carried out with 124 patients with a diagnosis of heart failure. Cronbach’s
alpha was high, at >0.9, and the interclass correlation coefficient was low, at 0.47. PELC
questionnaire scores showed differences depending on New York Heart Association func-
tional class (p<0.05) and, as posited in the a priori hypotheses, were moderately correlated
with emotional dimensions of QoL (0.53) and self-efficacy (0.43). Effect size for the clinically
improved subsample was moderate (0.67).
Conclusions
The results suggest that the Spanish version of the PELC questionnaire has appropriate
psychometric properties in terms of internal consistency and validity and is low in terms of
reproducibility and sensitivity to change.
Introduction
The impact of population ageing is both social and economic, as chronic disease, comorbidi-
ties and functional dependency represent a burden on healthcare systems and also have a
human cost in preventing individuals and communities from fulfilling their potential [1]. In
Spain, the latest health survey reports a 42.5% increase in chronic disease and a 47% increase
in functional dependency in people older than 65 years in the last 5 years [2].
In 2012 the European Regional Office of the World Health Organization (WHO) published
the Health 2020 framework programme [3] establishing strategic guidelines and priority areas
for political action regarding health and wellbeing until 2020. One specific goal stated in this
programme is citizen and patient empowerment, with empowerment defined as a “multidi-
mensional social process through which individuals and populations acquire a better under-
standing and control over their lives”. Thus, if patients are to be equipped to self-manage their
own health and play an active and informed role in decision-making, health literacy and access
to quality information are prior requirements. This programme also regards empowerment
and patient-focused care as key factors in improving health outcomes, increasing user satisfac-
tion, improving communication between professionals and patients, ensuring better adher-
ence with therapeutic plans and reducing healthcare use and costs. The WHO, furthermore,
emphasises the need to use strategies that empower patients with chronic diseases and also to
develop patient-reported outcome measures (PROMs) [4].
In the health field, the concept of empowerment has a long history. It was first adopted as a
key element in promoting health and later came to be applied as a way to enhance patient
autonomy and participation in decision-making regarding their health issues. The concept has
come into its own, however, in a current context of a growing burden of chronic pathologies
and the concomitant rise in healthcare costs [5–7].
Although various instruments are available to measure the empowerment of patients with
chronic diseases [8–14], all but one of the tools [14] were developed for a specific condition or
to be used within a specific specialty and none have as yet been developed in the Spanish
language.
The Patient Empowerment in Long-Term Conditions (PELC) was proposed by Small et al
[14] as a tool measure empowerment in chronic patients from a primary care perspective, with
responses scored using a 5-point Likert scale. Based on a model of patient-centred
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empowerment 5 dimensions covering 51 items were initially proposed, which, following psy-
chometric analysis, were reduced to 3 dimensions consisting of 47 items, as follows.
‘Positive attitude and sense of control’ (21 items), referring to changes experienced by
patients in regard to self-perceptions after diagnosis and how patients reduce the impact of dis-
ease in their lives and as a result gain greater self-control.
‘Knowledge and confidence in decision-making’ (13 items), referring to patient reports of
having sufficient knowledge and understanding to manage their condition and participate
appropriately in decision-making with their doctor.
A complex mixture of items relating to ‘enabling others’, ‘knowledge and understanding’
and ‘decision-making’ (13 items).
However, given the unclear nature of the 3-factor solution, Small et al(14) suggested that
the 47-item instrument be restricted to the total empowerment scale. (Reproduced in S1
Appendix).
The purpose of this study was to assess the feasibility, reliability, validity and sensitivity-to-




Quantitative, longitudinal, prospective, multi-centre psychometric study conducted between
June 2015 and June 2017 in 3 healthcare areas in Spain. Patients were recruited from inte-
grated HF programmes (IHFPs), defined as hospital-based and primary-care-based HF units
offering nursing care and structured monitoring by multidisciplinary teams [15,16].
Participants
The study population consisted of all patients with a confirmed HF diagnosis—according to
European Society of Cardiology guidelines [17]—meeting the following inclusion criteria:
patients hospitalized with a main HF diagnosis (initial admission or readmission), followed up
on discharge in an IHFP and who granted their informed consent. Exclusion criteria were as
follows: (a) patients with acute coronary syndrome on admission; (b) patients due for surgery
in the next 3 months for a valvular heart disease; (c) patients unable to take part in the study
due to their clinical status or previously diagnosed cognitive impairment; (d) patients for
whom a language barrier would make it difficult for them to complete the questionnaire; and
(e) patients aged under 18 years. We focussed the validation in patients with HF since this con-
dition has a high prevalence, elevated mortality and morbidity and imposes a significant bur-
den to the patients (poor health-related quality of life) and to the system (elevated medical
resource use and expenditure [1]
Questionnaire validation required recruiting between 2 and 10 times the number of items
in the instrument as participants in the study [18]. A sample of 97 participants was therefore
calculated for the pilot test, increased to 121 participants to take into account an estimated loss
of 20%.
Measurements
The PELC comprises 47 items scored according to a Likert scale ranging from 1 (totally dis-
agree) to 5 (totally agree). The final score ranges from a minimum of 47 to a maximum of 235
points, with higher scores indicating greater empowerment. The instrument has been trans-
lated and culturally adapted to the Spanish language [19] (reproduced in S2 Appendix)
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Criterion validity was assessed through measures that could hypothesize relationships with
the overall empowerment scale (or individual dimensions) based on existing theories and
empirical data as health-related QoL, self-care and self-efficacy [20]. Most predictions applied
to all the empowerment dimensions, but some referred only to specific dimensions. The com-
parative prediction measures used were the Hospital Anxiety and Depression Scale (HADS),
the Minnesota Living with Heart Failure Questionnaire (MLHFQ), the European Heart Failure
Self-care Behaviour Scale (EHFScBS) and the General Self-Efficacy Scale (GSES) for psychoso-
cial, health-related QoL, self-care and self-efficacy evaluations, respectively. These instruments
have been validated in Spanish patients and briefly described as follows.
The HADS [21] is a self-administered 14-item questionnaire, with a subscale each for anxi-
ety (7 odd-numbered items) and depression (7 even-numbered items), answered according to
a Likert scale ranging from 0 to 3. The overall questionnaire score ranges from 0 to 21 for each
subscale, with 0–7, 8–10, 11–14 and 15–21 reflecting no, mild, moderate or clinically relevant
anxiety/depression.
The MLHFQ [22] is a self-administered 21-item HF-specific questionnaire, with specific
subscales for physical (8 items) and emotional (5 items) aspects. Each item has 6 Likert-scale
response options ranging from 0 to 5 (best to worst health-related QoL). Minimum and maxi-
mum overall scores are 0 and 105, respectively.
The EHFScB [23] is a 12-item self-administered questionnaire on various aspects of patient
self-care, scored on a Likert scale between 1 (totally agree) and 5 (totally disagree). The overall
score ranges from 12 to 60, reflecting best and worst self-care, respectively.
The GSES [24], a 10-item questionnaire to evaluate stable feelings of personal competence
in effectively handling a wide range of stressful situations, is answered according to a Likert
scale ranging from 1 (not at all true) to 4 (exactly true). The overall score ranges from 10 to 40,
with higher scores reflecting greater self-efficacy.
For psychosocial evaluations we also used the Barthel Index [25] and the Pfeiffer Short Por-
table Mental Status Questionnaire (SPMSQ) [26]. The Barthel Index is a hetero-applied
10-item questionnaire that measures a person’s capacity to perform basic activities of daily liv-
ing, with the score reflecting a quantitative estimate of a person’s dependency level: 0–40
(severe dependency), 41–60 (moderate dependency), 61–99 (slight dependency) and 100
(independence). The Pfeiffer Questionnaire is a 10-item hetero-applied questionnaire that
measures possible cognitive impairment via general and personal questions, scored as: 0–2
errors (normal mental functioning), 3–7 errors (mild-moderate cognitive impairment) and
8–10 (severe cognitive impairment).
As sociodemographic variables we used age, sex, marital status, education, living circum-
stances and the presence of a caregiver. As clinical variables we used functional class according
to the New York Heart Association (NYHA), left ventricular ejection fraction (LVEF), N-ter-
minal pro-brain natriuretic peptide (NT-proBNP), comorbidities as assessed by the Charlson
comorbidity index (Charlson score: 0–1 (none comorbidity), 2 (low comorbidity) and equal or
greater than 3 (high comorbidity) [27], time since diagnosis, and pharmacological treatment.
NYHA class was evaluated using Goldman’s Specific Activity Scale [28] to standardize the
questions and so obtain a reproducible measure of NYHA status of patients with HF.
Data collection
Visits consisted of a baseline visit (24–48 hours after hospital admission) at week 0 (W0) and 2
follow-up visits at weeks 2 and 12 (W2 and W12, respectively).
At W0, sociodemographic and clinical variable data were collected for all 124 patients. The
PELC, MLHFQ, EHFScB, and GSES instruments were administered to the full sample of
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patients in order to be able to evaluate validity and internal consistency of the PELC
questionnaire.
At W2, patients were evaluated for clinical stability with regard to W0, with stability defined
as remaining in the same NYHA class [22,29]. The PELC questionnaire was administered to
the subsample of clinically stable patients in order to evaluate its reproducibility.
At W12, clinical data was collected and the PELC, MLHFQ and EHFScB questionnaires
were administered. To assess the PELC questionnaire’s sensitivity to change, patients were
classified into either a ‘clinically improved’ or ‘clinically non-improved’ subsample. Clinical
improvement was defined as a reduction of at least 1 NYHA class and no readmission during
follow-up for HF or other cardiovascular or decompensation problems requiring diuretic or
intravenous treatment, whereas clinical non-improvement was non-compliance with one or
more of the above criteria.
Data analysis
Baseline sociodemographic and clinical characteristics were described as absolute and relative
frequencies and means ± standard deviations for the full sample and subsamples. Data were
compared using bivariate tests (chi-square test, t-test and Wilcoxon test).
The PELC questionnaire items were descriptively analysed in order to explore instrument
feasibility in terms of percentage of patients who left items unanswered and percentage of
patients with maximum (ceiling effect) and minimum (floor effect) scores at the baseline visit
[22,29].
Instrument reliability was analysed by examining internal consistency and reproducibility.
The Cronbach alpha coefficient was used to evaluate internal consistency on the basis of base-
line data for the entire sample. Test-retest reproducibility was calculated using the intraclass
correlation coefficient (ICC) for the subsample of patients who remained stable from W0 to
W2. For both the Cronbach alpha and the ICC, which take values between 0 and 1, values
higher than 0.7 were considered to indicate good internal consistency and good stability over
time [30].
Criterion validity was evaluated using a Pearson correlation matrix for baseline clinical data
and PELC and other questionnaire responses [31,32]. Validity, which depicts relationships
between similar concepts, was reflected in moderate-to-high coefficients (>0.4) when conver-
gent. Our initial hypothesis was of convergence between the PELC questionnaire and NYHA
class, time since diagnosis, Charlson comorbidity index, HADS-Depression, MLHFQ and the
GSES. Validity, when divergent, was reflected in low coefficients (<0.4) for dimensions evalu-
ating a different construct, i.e., reflecting divergence between the PELC questionnaire and
HADS-Anxiety and the EHFScB.
The sensitivity-to-change analysis for the PELC, MLHFQ, and EHFScB instruments was
based on differences between W0 and W12. Means were compared using the t-test for paired
data. Effect size was calculated on the basis of the mean differences between baseline and fol-
low-up scores divided by the standard deviations of the baseline means, with values>0.8, 0.5
and 0.2 regarded as large, moderate and small, respectively [31,32].
Statistical analyses were performed using Statistical Analysis System (SAS) v. 9.4 (SAS Insti-
tute Inc., Cary, NC, USA) and the level of statistical significance was set as 0.05.
Ethical considerations
All participants received written information on the study aims and purpose and were asked
for their written informed consent. Participants were also informed of the possibility of
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withdrawing at any time. Confidentiality was guaranteed and, on inclusion, participants were
assigned an anonymous code which was used for all data collected on them.
The study was reviewed and approved by the research ethics committees of each centre
(Parc de Salut Mar: n˚ 2014/5916/I, Hospital Universitario de Bellvitge: PR 230/16, Hospital de
Sant Joan Despı́ Moisès Broggi: n˚ 16/349)
Results
Fig 1 depicts a flowchart showing the sample (n = 124) and subsamples and reflecting visits at
W0 (baseline) and W2 and W12 (follow-up).
Table 1 shows the baseline sociodemographic and clinical characteristics of the full sample
of patients and the different subsamples.
Regarding the clinically improved and non-improved subsamples, significant differences
were found with respect to NYHA class, time since diagnosis, LVEF, angiotensin converting
enzyme inhibitors (ACEI) treatment and anxiety. The clinically improved subsample com-
pared to the clinically non-improved subsample had a poorer baseline NYHA class (p<0.001),
a shorter time since diagnosis (p = 0.042), a higher proportion of LVEF values below 40%
(p = 0.038), a higher proportion of patients treated with ACEIs (p = 0.043) and less frequently
had clinically relevant anxiety (p = 0.01).
Feasibility
There was a higher proportion of unanswered items for the PELC (36.3%) compared to the
MLHFQ (1.6%), EHFScB (4%) and GSES (11.3%) instruments. Most scores were distributed
within the theoretical range for all the instruments. Floor-effect percentages were low for all
the instruments except for the EHFScB (4%) and MLHFQ_Emotional (5.6%). The highest ceil-
ing-effect percentages were for the MLHFQ-Physical and GSES, at 3.2% and 2.4%, respectively
(Table 2).
Fig 1. Study participant flowchart.
https://doi.org/10.1371/journal.pone.0233338.g001
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Table 1. Patient baseline sociodemographic and clinical characteristics.
Total sample (n = 124) Reliability subsample Sensitivity-to-change subsamples
Stable (n = 70) Clinically Improved (n = 48) Clinically Non-improved (n = 68)
Sex
Male 84 (68) 46 (66) 32 (68) 46 (68)
Female 40 (32) 24 (34) 16 (32) 44 (32)
Age (years) 70±12.3 70.2±12.8 68.5±12.3 70.8±12.2
Marital status
Partnered 64 (52) 38 (54) 23 (48) 37 (54.5)
Single/divorced/separated 32 (26) 15 (22) 15 (31) 15 (22)
Widowed 28 (22) 17 (24) 10 (21) 16 (23.5)
Education
Low literate 4 (3) 3 (3.5) 2 (4) 2 (3)
Primary 74 (60) 40 (57) 25 (52) 44 (65)
Secondary 23 (18.5) 15 (21.5) 11 (23) 12 (17)
Tertiary 17 (14) 9 (13) 7 (15) 8 (12)
NK 4 (3) 1 (1.5) 2 (4) 1 (1.5)
MV 2 (1.5) 2 (3) 1 (2) 1 (1.5)
Living circumstances
Lives alone (autonomous) 36 (29) 20 (28.5) 15 (31) 18 (26.5)
Lives with family (autonomous) 85 (69) 48 (68.5) 31 (65) 49 (72)
Lives with carer (dependent) 3 (2) 2 (3) 2 (4) 1 (1.5)
Barthel dependency index
Severe 3 (3) 1 (2) 2 (4) 1 (1.5)
Moderate 4 (3.5) 0 2 (4) 1 (1.5)
Minor 47 (38) 24 (34) 13 (27) 30 (44)
Independent 68 (55) 45 (64) 31 (65) 34 (50)
MV 2 (1.5) 0 0 2 (3)
Pfeiffer cognitive assessment
Normal 116 (93.5) 66 (94.3) 47 (98) 62 (91.2)
Mild-moderate impairment 5 (4) 3 (4.3) 1 (2) 3 (4.4)
Severe impairment 0 (0) 0 (0) 0 0 (0)
MV 3 (2.4) 1 (1.4) 0 3 (4.4)
NYHA class�
I 13 (11) 12 (17) 0 13 (19)
II 51 (41) 45 (64) 17 (35) 30 (44)
III 50 (40) 13 (19) 24 (50) 24 (35)
IV 10 (8) 0 7 (15) 1 (2)
Time since diagnosis (months)�
<1 51 (41) 23 (33) 27 (56) 21 (31)
1–12 19 (15) 12 (17) 8 (17) 9 (13)
13–24 12 (10) 10 (14) 2 (4) 8 (12)
25–36 8 (6) 6 (9) 3 (6) 5 (7)
>36 33 (27) 19 (27) 8 (17) 24 (35)
MV 1 (1) 0 0 1 (2)
LVEF (%)�
<30 25 (20) 15 (21) 11 (23) 14 (21)
30–39 25 (20) 11 (16) 16 (33) 8 (11)
40–49 23 (18.5) 14 (20) 8 (17) 13 (19)
(Continued)
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Table 1. (Continued)
Total sample (n = 124) Reliability subsample Sensitivity-to-change subsamples
Stable (n = 70) Clinically Improved (n = 48) Clinically Non-improved (n = 68)
�50 49 (39.5) 28 (40) 13 (27) 32 (47)
MV 2 (2) 2 (3) 0 1 (2)
Charlson comorbidity index
None 38 (31) 26 (37) 16 (33) 21 (31)
Low 51 (41) 29 (41) 21 (44) 25 (37)
High 34 (27) 14 (20) 11 (23) 21 (31)
MV 1 (1) 1 (2) 0 1 (1)
NT-proBNP (pg/mL) 3662 [1978–7516] 3304 [1272–7170] 4738 [2296–8325] 3447 [2146–6649]
Treatments
β-blockers 100 (81) 60 (86) 38 (79) 55 (81)
ACEI/ARB � 75 (61) 45 (64) 35 (73) 37 (54)
MRA 42 (34) 25 (36) 17 (35) 22 (32)
Diuretics 117 (94) 64 (91) 47 (98) 63 (93)
HADS-Anxiety�
Normal 28 (22.6) 21 (30) 7 (14.6) 20 (29.5)
Borderline case 54(43.5)33 32 (45.7) 19 (39.6) 32 (47)
Abnormal case (26,6) 13 (18.6) 18 (37.5) 13 (19)
MV 9 (7,3) 4 (5.7) 4 (8.3) 4 (4.5)
HADS-Depression
Normal 13 (10.5) 5 (7) 8 (17) 5 (7)
Borderline case 67 (54) 41 (59) 23 (48) 40 (59)
Abnormal case 34 (27.5) 19 (27) 14 (29) 19 (28)
MV 10 (8) 5 (7) 3 (6) 4 (6)
Categorical variables are expressed as n (%) and continuous variables as means±standard or median deviations [interquartile range].
� Statistically significant differences (X2) between the ‘clinically improved’ and ‘clinically non-improved’ subsamples. NYHA: New York Heart Association, LVEF: left
ventricular ejection fraction; NT-proBNP: N-terminal pro-brain natriuretic peptide; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor
blocker; MRA: mineralocorticoid/aldosterone receptor antagonist; HADS: Hospital Anxiety and Depression Scale; NK: not known; MV: missing values.
https://doi.org/10.1371/journal.pone.0233338.t001
Table 2. Scores and feasibility coefficients for the MLHFQ, EHFScB, GSES and PELC instruments (n = 124).
Instruments Median±SD % ı́tems with MV Feasibility
Interval Floor % Ceiling %
MLHFQ
Physical 25.7±10.7 1.6 0–40 3.2 3.2
Emotional 11.1±6.9 1.6 0–25 5.6 0.8
Total 56.3±22.5 1.6 0–99 1.6 0.8
EHFScB 30.1±11.3 4 12–58 4 0.8
GSES 27.02±6.4 11.3 12–40 0.8 2.4
PELC 161.2±32.1 36.3 78–221 0.8 0.8
MLHFQ: Minnesota Living with Heart Failure Questionnaire; EHFScB: European Heart Failure Self-care Behaviour Scale; GSES: General Self-Efficacy Scale; PELC:
Questionnaire on Patient Empowerment in Long-Term Conditions; SD: standard deviation; MV: missing values;
https://doi.org/10.1371/journal.pone.0233338.t002
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Reliability
Cronbach’s alpha was high for all the instruments, at 0.84–0.91 for the MLHFQ, 0.80 for the
EHFScB, 0.91 for the GSES and 0.93 for the PELC. For the PELC questionnaire, the value for
the ICC was low (0.47) for the clinically stable subsample. (Table 3).
Convergent and divergent validity. The correlation matrix for the PELC and the other
questionnaires (Table 4) shows that some of the initial hypotheses proposed as convergent
were confirmed. The GSES, MLHFQ-Physical and MLHFQ-Emotional questionnaires, with
results>0.4, correlated with the PELC, but not the HADS-Depression questionnaire. The
hypotheses proposed as divergent were confirmed for EHFScB, with results<0.4, but not for
HADS-Anxiety.
As for the clinical variables, time since diagnosis and comorbidities obtained correlations
<0.4, indicating that the corresponding hypotheses were not confirmed (Table 4). Only score
differences according to NYHA were statistically significant in all cases (p = 0.04) (Fig 2).
Sensitivity to change
Score differences for the MLHFQ, EHFScB and PELC questionnaires between baseline and
W12 for the clinically improved subsample were statistically significant (Table 5), with high
effect size values obtained for the MLHFQ and EHFScB and a more moderate value
obtained for the PELC questionnaire. For the clinically non-improved subsample, there
were no significant changes in effect size values for the PELC and MLHFQ-Emotional,
whereas effect size changes were moderate for the EHFScB, MLHFQ overall and
MLHFQ-Emotional.
Table 3. Reliability for the PELC instrument (n = 124).
Instruments Reliability
Cronbach ICC�
PELC 0.93 0.47 (0.06–0.74)
PELC: Questionnaire on Patient Empowerment in Long-Term Conditions; ICC: intraclass correlation coefficient.
�The ICC was calculated for clinically stable patients between W0 and W2 (n = 70)
https://doi.org/10.1371/journal.pone.0233338.t003
Table 4. Multifeature-multimethod Pearson correlation matrix evaluating the PELC questionnaire validity (n = 124).
PELC







Time since diagnosis 0.28
Charlson comorbidity index -0.19
PELC: Questionnaire on Patient Empowerment in Long-Term Conditions; MLHFQ: Minnesota Living with Heart Failure Questionnaire; EHFScB: European Heart
Failure Self-care Behaviour Scale; GSES: General Self-Efficacy Scale; HADS: Hospital Anxiety and Depression Scale; LVEF: left ventricular ejection fraction; NT-
proBNP: N-terminal pro-brain natriuretic peptide
https://doi.org/10.1371/journal.pone.0233338.t004
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Discussion
This study describes an evaluation of the psychometric properties of the Spanish version of the
PELC questionnaire, with results indicating a high degree of internal consistency, low repro-
ducibility, and moderate sensitivity to change.
The feasibility results reflected a high percentage of missing values. This may be due to the
length of the PELC questionnaire, which would probably benefit from a reduced number of
items to make it more usable in clinical practice. There were differences in the floor effect with
respect to other instruments, but differences in the ceiling effect were smaller. Although these
results seem to contradict the theoretical advantage of specific over generic instruments, they
may be affected by the sample size [22,29].
Our validation results are not comparable to those for validation of the original version(14),
as only internal consistency and construct validity were evaluated in the latter case.
A Cronbach alpha value of 0.82, reflecting internal consistency, was obtained for the origi-
nal PELC questionnaire [14], contrasting with the improved Cronbach alpha value of 0.93
obtained for this Spanish version—improved even regarding the other instruments, most of
which are specific to patients with HF.
Reliability results, at<0.5, were not satisfactory, however. The 2 possible explanations for
this finding are a high percentage of missing values and a sample size that was too small to
meet the requirement of patients remaining stable.
Fig 2. Relationship between NYHA class and the PELC questionnaire score expressed as means (95% confidence
interval; p = 0.04).
https://doi.org/10.1371/journal.pone.0233338.g002
Table 5. Sensitivity-to-change estimators for the clinically improved and clinically non-improved subsamples for the MLHFQ, EHFScB and PELC instruments.
Improved subsample (n = 48) Non-improved subsample (n = 68)
Change (mean+SD) p (Student t-test) ES Change (mean+SD) p (Student t-test) ES
MLHFQ
Physical 13.5±11.4 < .001 1.39 5.27±9.94 < .001 0.46
Emotional 4.5±6.2 < .001 0.64 0.12±8.46 .9 0.02
Total 26.2±21.4 < .001 1.26 8.69±20.59 .002 0.36
MLHFQ: Minnesota Living with Heart Failure Questionnaire; EHFScB: European Heart Failure Self-care Behaviour Scale; GSES: General Self-Efficacy Scale; PELC:
Questionnaire on Patient Empowerment in Long-Term Conditions; SD: standard deviation; ES: effect size.
https://doi.org/10.1371/journal.pone.0233338.t005
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Regarding validity, the challenge was that, in the absence of a standard empowerment
instrument validated in Spanish with which to establish correlations, our hypotheses had to be
based on those of the original validation [14] and on interrelations—which are not always lin-
ear—established between empowerment, self-care, self-efficacy and QoL [20].
Unlike the results for the original version [14], time since diagnosis and comorbidities were
not associated with greater empowerment and lesser empowerment, respectively. The charac-
teristics of the patients in our sample may have caused this divergence in results.
Sensitivity to change, as reflected in the overall coefficient of 0.64, can be regarded as mod-
erate according to criteria defined by Cohen [33]. This value is lower than those obtained for
the QoL and self-care questionnaires, for which effects were not only greater (above 1 for
both), but also greater than reported in previous studies [22,29].
The main limitation of this study is sample size, although some authors recommend 2 to 10
respondents per item [18], the minimum number recommend is 5 per item [34,35]. In this case,
the number of items was 47, so the optimal number of subjects to be included in the study would
have been 235 to 470. We included 124 participants, with a ratio 2.63 participants / items.
The limitation is especially relevant to support the factor analysis, larger samples are
required. At least 200 cases are recommended in optimal conditions of high communalities
and well-determined factors, in cases of low communalities and little-determined factors this
number could be 500, which it didn´t allow a factor analysis in optimal conditions [36,37].
The clinically stable subsample was based only on NYHA functional categories, on the
assumption that perceived empowerment would not change in patients with the same func-
tional capacity. Although the metric characteristics of the NYHA classification are not well
known [38], the fact that it is broadly acknowledged to be variable in use and that there is little
evidence of its capacity to detect minimum clinically relevant differences [29] may mean that
the reproducibility of the PELC instrument may, in our case, be underestimated. Nonetheless,
the NYHA is widely used in routine practice to evaluate changes in patient status from a pro-
fessional perspective. The same variable of a change in NYHA status (as well as other indirect
variables, namely, readmission and decompensation) was used for the sensitivity-to-change
subsamples of clinically improved and clinically non-improved patients. As for the validity
analysis, the lack of a gold standard for Spanish meant that we relied on the literature to deter-
mine characteristics for our study that are associated with empowerment [20].
With regards to the disease, the original questionnaire was validated in a chronic heteroge-
neous patient population (diabetes, asthma and ischemic heart disease). In our study we decided
to carry out the validation of the instrument only in patients with HF in the vulnerable phase. The
primary motivation of selecting this cohort was the existence of validated instruments to measure
self-care in HF patients, allowing for direct comparison between self-care behavior measurements
and empowerment evaluation. The selection of this specific cohort in the vulnerable phase may be
a limitation of our study and may limit applicability of the results in other patient populations. In
this regard, other groups advocate for disease-specific questionnaires. However, we believe that
generic instruments, validated in cohorts including patients with multiple chronic conditions are
preferred and thus further studies including these mixed population are necessary.
Finally, the bias resulting from missing responses and the phenomenon of social desirability
are common problems in self-reported questionnaires administered to patients [39].
Conclusion
Our preliminary validation study suggests, as the original instrument, that ambiguities remain
about the structure of the scale and a more complete evaluation of the psychometric quality of
the scale is required.
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Our results suggest that the psychometric properties of the transculturally adapted and vali-
dated PELC questionnaire are appropriate in terms of internal consistency and validity and
low in terms of reproducibility and sensitivity to change. The main limitation of the question-
naire is the large number of items, for which reason a shorter version would be useful both in
reducing the burden on respondents and enhancing data quality.
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